MBX Biosciences is a preclinical-stage biotech company that creates therapies to treat rare endocrine diseases.
MBX Biosciences is a biotechnology company that develops therapies to treat rare endocrine diseases where there is inadequate treatment available. It focuses on the discovery, development, and commercialization of first-in-class endocrine therapeutics.The company was founded in 2018 and headquartered in Carmel, Indiana.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 14, 2022 | Series B | $115M | 6 |
Wellington Management
|
— | Detail |
| Jul 27, 2020 | Series A | $34.60M | 6 |
Frazier Healthcare Partners
|
— | Detail |
| Apr 25, 2019 | Debt Financing | $25.30M | — | — | — | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Wellington Management
|
Yes | Series B |
Frazier Healthcare Partners
|
Yes | Series A |
Norwest Venture Partners
|
— | Series B |
Frazier Life Sciences
|
— | Series B |
New Enterprise Associates
|
— | Series B |
OrbiMed
|
— | Series B |
RA Capital Management
|
— | Series B |
BioCrossroads
|
— | Series A |
Indiana University Philanthropic Venture Fund
|
— | Series A |
Twilight Venture Partners
|
— | Series A |